Malignant Mesothelioma — Trials

Malignant Mesothelioma — Trials · CancerIndex

Clinical trials

Registered studies

478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 55
Ph III recruiting: 1
Growth YoY: —
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.4%
Trials / 1,000 deaths: 45.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (81)

clinicaltrialsPublishedShowing 51–55 of 55 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03546426	Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies(MESOVAX)	active not recruiting	Phase 1	18	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER	1	Oct 1, 2024	clinicaltrials
NCT06452160	A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors	recruiting	Phase 1	103	BridGene Biosciences Inc.INDUSTRY